Preclinical
PHP53-nb
Therapeutic humanized camelid nanobody
TNBC and other TP53-altered solid tumors
Lead candidate. Preclinical package advancing toward planned IND-enabling work, with Phase I anticipated in 2027.
Pipeline
From peptide discovery to the clinic
PHP53-nb is the lead candidate. Behind it sits a reusable nanobody chassis and a p53-reactivating payload that can, in principle, support a broader pipeline of intracellular biologics.
Integrated
3-NAntC
p53-reactivating peptide payload
Multi-indication, starting with TNBC
Genetically engrafted into the nanobody scaffold — no linkers, post-modifications, or extra manufacturing steps.
Platform
GEN01-AD
Humanized camelid nanobody delivery platform
Modular intracellular peptide delivery
Reusable architecture for additional payloads beyond PHP53-nb, including future multi-specific constructs.
Stage bars are illustrative of company-stated development status, not regulatory designations. PHP53-nb is investigational.
Development timeline
Years 1–5
Peptide discovery & screening
More than five years screening and refining p53-reactivating peptide candidates, culminating in 3-NAntC.
Years 6–7
GEN01-AD platform
Two years designing and scaling a humanized camelid nanobody delivery platform for stable, linker-free peptide delivery.
Year 8
PHP53-nb emerges
The lead candidate demonstrates encouraging preclinical results in TNBC and other aggressive cancers, including pancreatic models.
2026
Preclinical studies
Planned completion of the core preclinical package, including efficacy, mechanism, toxicity, characterization, and biodistribution.
2027
Clinical trials
Anticipated start of Phase I first-in-human studies, subject to regulatory review.